Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Endothelium

Mechanism of Endothelial Nitric Oxide Synthase Phosphorylation and Activation by Thrombin

Evangeline D. Motley, Kunie Eguchi, Myla M. Patterson, Phillip D. Palmer, Hiroyuki Suzuki, Satoru Eguchi
Download PDF
https://doi.org/10.1161/01.HYP.0000255954.80025.34
Hypertension. 2007;49:577-583
Originally published February 15, 2007
Evangeline D. Motley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kunie Eguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myla M. Patterson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phillip D. Palmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroyuki Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoru Eguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Thrombin has been shown to activate endothelial NO synthase (eNOS) leading to endothelium-dependent vasorelaxation. In addition to its activation by Ca2+/calmodulin, eNOS has several regulatory sites. Ser1179 phosphorylation of eNOS by the phosphatidylinositol 3-kinase-dependent Akt stimulates its catalytic activity. In this study, we have elucidated the signaling mechanism of thrombin-induced phosphorylation of eNOS in the regulation of NO production. Immunoblot analysis showed that thrombin rapidly phosphorylates eNOS at Ser1179 in cultured bovine aortic endothelial cells. Also, thrombin was unable to stimulate eNOS if the Ser1179 was mutated to Ala. Akt is phosphorylated in response to thrombin at Ser473 at a later time point than eNOS. In this regard, a phosphatidylinositol 3-kinase inhibitor, LY294002, blocked Akt phosphorylation without affecting eNOS phosphorylation and cGMP production by thrombin. The Ca2+ ionophore A23187 stimulated eNOS phosphorylation, as well as cGMP production, and pretreatment with intracellular or extracellular Ca2+ chelators inhibited thrombin-induced eNOS phosphorylation and cGMP production. Moreover, infection of bovine aortic endothelial cell with adenovirus encoding dominant-negative mutants of protein kinase C (PKC)α and PKCδ or pretreatment of bovine aortic endothelial cells with PKC inhibitors revealed that PKCδ is indispensable for thrombin-induced eNOS phosphorylation and activation. From these data, we concluded that thrombin induces the Ser1179 phosphorylation-dependent eNOS activation through a Ca2+-dependent, PKCδ-sensitive, but phosphatidylinositol 3-kinase/Akt-independent pathway.

  • thrombin
  • NO
  • endothelial NO synthase
  • protein kinase C

Thrombin has been shown to induce endothelium-dependent relaxation in many types of vascular tissue.1,2 In most cases, production of an endothelium-derived relaxing factor, NO, is, at least in part, responsible for the thrombin-induced vasorelaxation.3,4 NO is the most potent endogenous vasodilator known. NO also inhibits platelet adherence and aggregation, reduces adherence of leukocytes to the endothelium, and suppresses proliferation of vascular smooth muscle cells.5 In this regard, endothelial dysfunction in various cardiovascular disorders is characterized by decreased NO availability,5 justifying the number of studies dealing with signal transduction involved in the regulation of endothelial NO synthase (eNOS), the enzyme responsible for endothelial NO production.6,7 In addition to well-known Ca2+/calmodulin-dependent activation of eNOS, recent studies revealed additional modes of posttranslational eNOS regulation involving its phosphorylation, dimerization, protein/protein interactions, and subcellular localization.6,7 For example, eNOS phosphorylation at Ser1177(human)/1179(bovine) by phosphatidylinositol 3-kinase (PI3-K)–dependent Akt plays a critical role in its activation by various agonists, such as vascular endothelial growth factor.6

Much effort has been made to delineate the molecular mechanisms by which thrombin affects cellular function. Thrombin exerts its cellular effects by activation of G protein-coupled protease-activated receptors.8,9 Through specific protease-activated receptors coupled to various G proteins (Gi, Go, Gq, and G12/13), thrombin induces an array of intracellular signal transduction pathways in endothelial cells, such as phospholipase C, phospholipase A2 protein kinase C (PKC), small G proteins (Ras, Rho, and Rac), PI3-K, and several protein kinases including Akt/protein kinase B, Ca2+/calmodulin-dependent kinase II, and mitogen-activated protein kinases.10,11 In the present study, we have investigated the roles of PI3-K, Akt, Ca2+, and specific PKC isoforms in regulating eNOS Ser1179 phosphorylation by thrombin. Here, we demonstrated that thrombin induces phosphorylation and activation of eNOS through a Ca2+-dependent and PKCδ-sensitive pathway that is independent of the PI3-K/Akt pathway.

Methods

Reagents

Thrombin from bovine plasma and EGTA were purchased from Sigma Chemical Co. NG-nitro-l-arginine methyl ester, phorbol 12-myristrate 13-acetate (PMA), LY294002, A23187, 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetraacetoxy-methyl ester, GF109203X, and rottlerin were purchased from Calbiochem. YM-254890 was a gift from Astellas Pharma Inc. Antibodies that selectively recognize Ser1179-phosphorylated eNOS, Thr497-phosphorylated eNOS, Ser473-phosphorylated Akt, and total Akt were purchased from Cell Signaling Technology, and antibody to detect Tyr311-phosphorylated PKCδ was purchased from Biosource International. Total eNOS antibody was purchased from BD Transduction Laboratories. Total PKCα, PKCδ, and extracellular signal-regulated kinase 2 antibodies were purchased from Santa Cruz Biotechnology, Inc.

Cell Culture

Bovine aortic endothelial cells (BAECs) were purchased from BioWhittaker and cultured in DMEM containing 10% FBS, penicillin, and streptomycin. Cells from passage 4 to 12 were grown to ≈90% confluence and serum depleted for 48 hours before the experiments. Cultured human umbilical vein endothelial cells were a gift from Dr Yi Wu (Temple University School of Medicine). Primary vascular smooth muscle cells (VSMCs) from rat aorta were obtained by the explant methods and subcultured for the experiment as described previously.12

Immunoblotting

Cell lysates were subjected to SDS-PAGE gel electrophoresis and electrophoretically transferred to a nitrocellulose membrane as described previously.12 The membranes were then exposed to primary antibodies overnight at 4°C. After incubation with the peroxidase-linked secondary antibody for 1 hour at room temperature, immunoreactive proteins were visualized by enhanced chemiluminescence reagent.13 Results were expressed as percentage increase in which the maximum response to thrombin (10 U/mL) is defined as 100%, because the basal signals are more varied depending on film exposure than the stimulated signals.

Adenovirus Infection

The generation and characterization of adenovirus encoding wild-type and dominant-negative mutants of PKCα and PKCδ were described in detail elsewhere.14 Adenovirus encoding wild-type and the Ser1179 mutant, S1179A, were kindly provided by Dr William Sessa.15 BAECs or VSMCs were infected with the adenovirus for 2 days as described previously before treatment with thrombin.16

Intracellular cGMP Accumulation

BAECs were incubated with agonists at 37°C for 20 minutes in the presence of 0.5 mmol/L of methylisobutylxanthine,17 and intracellular cGMP was determined using an enzyme immunoassay kit (Cayman Chemical) under the manufacturer’s instruction. Results were expressed as percentage increase in which the maximum response to thrombin (10 U/mL) is defined as 100%.

Statistical Analysis of Data

Results shown in the blots are representative of ≥3 independent experiments. Densitometry data and cGMP data were analyzed using 1-way ANOVA with a significance level of P<0.05 (results shown are the mean±SEM of data from ≥3 separate experiments).

Results

Thrombin Induces Ser1179 Phosphorylation and Activation of eNOS

First, we examined whether or not thrombin phosphorylates eNOS at Ser1179, a catalytically positive regulatory site, in BAECs. As shown in Figure 1A, thrombin stimulated eNOS phosphorylation in a concentration-dependent manner. Figure 1B demonstrates that thrombin stimulates a significant increase in cGMP production that was completely inhibited by an eNOS inhibitor, NG-nitro-l-arginine methyl ester. To examine the functional relevance of Ser1179 phosphorylation of eNOS by thrombin, cultured rat VSMCs with no detectable eNOS expression were infected with adenovirus encoding wild-type or S1179A eNOS, and thrombin-induced cGMP production was evaluated. Despite comparable expression and induction of equivalent basal cGMP production, thrombin was able to further stimulate cGMP production in VSMCs expressing wild-type eNOS but not in VSMCs expressing S1179A, suggesting a positive contribution of Ser1179 phosphorylation in eNOS activation by thrombin (Figure 1C).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. The effect of thrombin on eNOS phosphorylation and cGMP formation. BAECs were stimulated with the indicated concentrations of thrombin for 1 minute, and (A) phosphorylation of eNOS at Ser1179 was determined using immunoblot analysis with a phosphospecific antibody, or (B) cGMP was measured as described in the Methods section. BAECs were also pretreated with the eNOS inhibitor NG-nitro-l-arginine methyl ester (100 μmol/L) for 30 minutes and stimulated with thrombin (10 U/mL) for 20 minutes. C, VSMCs infected with adenovirus encoding eNOS (WT), eNOS-S1179A (SA), or control vector (Vec) were stimulated with thrombin (10 U/mL) for 20 minutes, and cGMP concentrations were measured. Also, expression of eNOS in the infected VSMCs was evaluated. The data shown are mean±SEM (*P<0.05).

Thrombin-Induced Phosphorylation and Activation of eNOS Is Independent From the PI3-K/Akt Pathway

Because eNOS phosphorylation at Ser1179 and subsequent eNOS activation are mediated by PI3-K/Akt activation in response to several distinct eNOS activators, such as vascular endothelial growth factor, in cultured endothelial cells,6 we investigated whether thrombin activates Akt and whether the activation precedes eNOS phosphorylation. Activation of Akt was assessed by its phosphorylation at Ser473. As shown in Figure 2A and 2B, thrombin-induced eNOS phosphorylation could be observed as early as 0.5 minutes with maximum phosphorylation occurring at 1 minute. In contrast, we observed that thrombin induces the phosphorylation of Akt as early as 5 minutes (Figure 2A and 2B), which was much later than the thrombin-induced phosphorylation of eNOS (Figure 2C). These data indicate that Akt may not participate in the phosphorylation of eNOS by thrombin in BAECs.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Time-dependent effect of thrombin on eNOS and Akt phosphorylation. BAECs were stimulated with 10 U/mL of thrombin for the indicated time points, and phosphorylation of (A) eNOS at Ser1179 and (B) Akt at Ser473 was determined using immunoblot analysis with phosphospecific antibodies. C, The densitometric analysis of the phosphorylation of eNOS and Akt. The data shown are mean±SEM (*P<0.05).

To further explore our interpretation that the PI3-K/Akt signaling pathway is not required for thrombin-induced eNOS phosphorylation, we pretreated the BAECs with LY294002, an inhibitor of PI3-K before exposure to thrombin. Figure 3A and 3B show that LY294002 did not inhibit thrombin-induced eNOS phosphorylation at Ser1179 but that thrombin-induced Akt phosphorylation was completely inhibited by the agent. In addition, LY294002 had no inhibitory effect on cGMP production stimulated by thrombin in BAECs (Figure 3B). These studies demonstrate that thrombin activation of the PI3-K/Akt pathway is not essential for thrombin-induced phosphorylation and activation of eNOS in BAECs.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Effect of LY294002, a PI3-K inhibitor, on the thrombin-induced phosphorylation of eNOS and Akt. BAECs were pretreated with LY294002 (10 μmol/L) for 30 minutes and stimulated with 10 U/mL thrombin for the indicated time points. A, Phosphorylation of eNOS at Ser1179 and Akt at Ser473 was determined using immunoblot analysis with phosphospecific antibodies. B, Percent phosphorylation of eNOS at 1 minute is shown in the first panel by densitometric analysis, and the percent cGMP production for 20 minutes is shown in the second panel using an assay kit. The data shown are mean±SEM (*P<0.05).

Involvement of Intracellular Calcium in eNOS Phosphorylation and Activation

Thrombin is known to cause the intracellular release of Ca2+ stores and the influx of extracellular Ca2+ in endothelial cells.18,19 This may stimulate eNOS activity through a Ca2+/calmodulin-dependent mechanism, whereas the possible contribution of intracellular Ca2+ to the phosphorylation of eNOS remains uncertain. We observed that A23187, a Ca2+ ionophore, stimulated eNOS phosphorylation at Ser1179 in BAECs (Figure 4A). In Figure 4B, we observed a comparable increase in the production of cGMP by thrombin and A23187. Moreover, we found a critical role for Ca2+ in the thrombin-induced phosphorylation of eNOS. Pretreatment with an intracellular Ca2+ chelator, 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetraacetoxy-methyl ester (Figure 4C), or an extracellular Ca2+ chelator, EGTA (Figure 4D), inhibits eNOS phosphorylation. We confirmed that the thrombin-induced production of cGMP was inhibited by these chelators as well (Figure 4E and 4F). These data suggest that both intracellular Ca2+ stores and influx of extracellular Ca2+ are required for Ser1179 phosphorylation and activation of eNOS by thrombin.

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. Involvement of Ca2+ in thrombin-induced eNOS phosphorylation. BAECs were stimulated with (A) 10 μmol/L of A23187, a Ca2+ ionophore, for 1 minute, and eNOS phosphoprylation at Ser1179 was observed. B, A23187 was also used to stimulate cGMP production. BAECs were pretreated with 10 μmol/L 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetraacetoxy-methyl ester, an intracellular Ca2+ chelator, for 30 minutes (C and E) or 5 mmol/L EGTA, an extra Ca2+ chelator, for 3 minutes (D and F) and stimulated with or without 10 U/mL thrombin for 1 minute (C and D) or for 20 minutes (E and F). eNOS phosphorylation at Ser1179 was observed by immunoblot analysis with a phosphospecific antibody (C and D), as well as cGMP production using an assay kit (E and F). The data shown are mean±SEM (*P<0.05 vs basal; †P<0.05 vs stimulated control).

The Role of PKCδ in the Thrombin-Induced Phosphorylation and Activation of eNOS

Thrombin activates several PKC isoforms, such as PKCα and PKCδ, in endothelial cells, and each isoform appears to mediate distinct downstream functions.11 We observed that rottlerin, a PKCδ inhibitor, attenuates the phosphorylation of eNOS. Rottlerin, but not LY294002, also blocked the phosphorylation of eNOS by thrombin in human umbilical vein endothelial cells (Figure IA, available online at http://hyper.ahajournals.org). In contrast, nonsubtype selective PKC inhibitor GF10932X had only a small inhibitory effect on the phosphorylation of Ser1179 eNOS (Figure 5A). Thrombin-induced cGMP production was almost completely inhibited by rottlerin (Figure 5B), consistent with the importance of PKCδ in eNOS activation by thrombin. In contrast to A23187, a nonsubtype selective PKC activator, PMA, dephosphorylated eNOS at Ser1179 (Figure 5C). When both agonists are combined, A23187 seems to have the dominate effect on the Ser1179 phosphorylation of eNOS. In addition, PMA did not stimulate cGMP production in BAECs (Figure 5D). We also observed that thrombin rapidly induced phosphorylation of PKCδ Tyr311, the site linked to its activity20 (Figure IB). To study the relationship between Ca2+ and PKCδ in eNOS phosphorylation, the effect of rottlerin on A23187-induced eNOS phosphorylation was examined. Rottlerin markedly inhibited A23187-induced eNOS phosphorylation in BAECs (Figure IC).

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 5. The effect of PKC inhibitors on thrombin-induced phosphorylation of eNOS. BAECs were pretreated with 10 μmol/L rottlerin, a PKCδ inhibitor, or 2 μmol/L GF109203X, a general PKC inhibitor, for 30 minutes and then stimulated with 10 U/mL thrombin for 1 minute (A) or 20 minutes (B). A, Phosphorylation of eNOS at Ser1179 was observed using immunoblot analysis, and (B) cGMP was measured using an assay kit. The data shown are mean±SEM (*P<0.05 vs basal; †P<0.05 vs stimulated control). C, BAECs were stimulated with 10 μmol/L A23187, 1 μmol/L PMA, or combination of both for 1 minute. Phosphorylation of eNOS at Ser1179 was observed using immunoblot analysis. D, BAECs were stimulated with 1 μmol/L of PMA or 10 U/mL of thrombin for 20 minutes. cGMP was measured using an assay kit. The data shown are mean±SEM (*P<0.05 vs basal).

To complement these studies with rottlerin, which may have nonspecific effects, the role of PKCδ was further studied by infection of BAECs with adenovirus encoding dominant-negative (dn) mutants of PKCδ or PKCα. As shown in Figure 6A, infection of BAECs with dnPKCα adenovirus enhanced both basal- and thrombin-induced Ser1179 phosphorylation of eNOS, whereas infection of BAECs with dnPKCδ adenovirus inhibited thrombin-induced Ser1179 phosphorylation of eNOS. We also observe that dnPKCδ, but not dnPKCα, causes a significant reduction in cGMP production induced by thrombin in BAECs (Figure 6B). These findings suggest that PKC isoforms have distinct regulatory roles in eNOS phosphorylation and activation, and the positive regulatory role of PKCδ on Ser1179 is overridden if other negative regulatory PKCs, such as PKCα, are simultaneously activated by PMA in BAECs. Because reciprocal negative eNOS regulation through eNOS Thr497 phosphorylation has been reported,21 we have further examined phosphorylation of this site by thrombin in BAECs pretreated with or without PMA. Consistent with a recent report,22 thrombin also stimulated eNOS Thr497 phosphorylation. Pretreatment with PMA further enhanced Thr497 phosphorylation but partially inhibited Ser1179 phosphorylation induced by thrombin (Figure ID).

Figure6
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 6. The effects of dominant negative (dn) PKC and a Gq inhibitor on thrombin-induced phosphorylation and activation of eNOS. BAECs were infected with adenovirus encoding dn adenoviruses for PKCα or PKCδ (100 multiplicities of infection) for 48 hours and then stimulated with 10 U/mL of thrombin for 1 minute (A) or for 20 minutes (B). BAECs were pretreated with or without 10 μmol/L YM-254890 for 10 minutes and stimulated with or without 10 U/mL thrombin for 1 minute (C) or 20 minutes (D). eNOS phosphorylation at Ser1179 was observed by immunoblot analysis with a phosphospecific antibody (A and C). These data are representative of 3 separate experiments giving similar results. cGMP production was measured using an assay kit (B and D). The data shown are mean±SEM (*P<0.05 vs basal; †P<0.05 vs stimulated control).

The requirement of Ca2+ and a PKC isoform for thrombin-induced Ser1179 eNOS phosphorylation suggests that Gq may be required for the phosphorylation of eNOS at Ser1179. In fact, a selective Gq inhibitor, YM-254890,23 inhibited thrombin-induced Ser1179 phosphorylation of eNOS (Figure 6C). YM-254890 also blocked thrombin-induced cGMP production in BAECs (Figure 6D). Taken together, these data indicate that, in addition to a previously known Ca2+/calmodulin-dependent mechanism, phosphorylation of Ser1179 eNOS is mediated through the activation of Gq and subsequent elevation of intracellular Ca2+ combined with the activation of PKCδ, which are indispensable for activation of eNOS by thrombin in endothelial cells (Figure 7).

Figure7
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 7. Proposed signal transduction cascade by which thrombin mediates eNOS activation. CaM indicates calmodulin.

Discussion

In the present study, we have demonstrated that thrombin induces eNOS Ser1179 phosphorylation and activation through a Ca2+-dependent, PKCδ sensitive, but PI3-K/Akt independent, pathway. It has been shown that eNOS Ser1179 phosphorylation through the PI3-K-dependent Akt is indispensable for eNOS activation by many factors, such as vascular endothelial growth factor, estrogen, and shear stress.6 However, in this study, we have demonstrated that the PI3-K/Akt pathway is not necessary for eNOS regulation by thrombin in endothelial cells. Several lines of evidence support this notion: (1) Akt phosphorylation occurs later than eNOS phosphorylation, rather than preceding it; (2) a PI3-K inhibitor, LY294002, did not inhibit thrombin-induced Ser1179 phosphorylation of eNOS, although it inhibited the phosphorylation of Akt induced by thrombin under the same condition; and (3) LY294002 does not inhibit thrombin-induced cGMP production, which is known to result from eNOS activation. We verified that thrombin induced cGMP production via eNOS activation by using NG-nitro-l-arginine methyl ester, an eNOS inhibitor, which attenuated thrombin-induced cGMP production.

Thrombin is known to cause the intracellular release of Ca2+ stores and the influx of extracellular Ca2+ in endothelial cells.18,19 This may be sufficient to stimulate eNOS activity through a Ca2+/calmodulin-dependent mechanism. Although phosphorylation of eNOS by thrombin at Ser1179 has been demonstrated recently,24 the functional relevance of this phosphorylation is uncertain. Our experiment using the S1179A mutant strongly suggests the relevance of Ser1179 phosphorylation in eNOS activation by thrombin. We also confirmed recently the requirement of Ser1179 phosphorylation for eNOS activation via a Gq-coupled angiotensin II receptor.25 Moreover, the relationship between Ca2+ and the regulation of eNOS phosphorylation by G protein-coupled receptors (GPCRs) has not been established previously. Therefore, our findings are novel in that Ca2+ is also required for eNOS activation by a GPCR agonist through its input on the phosphorylation of Ser1179.

In addition to Akt, several protein kinases have been shown recently to phosphorylate eNOS at Ser1179. These include protein kinase A, 5′-AMP-activated protein kinase, and calmodulin-dependent kinase II.6,7 Because the amino acid sequences surrounding the Ser1179 site do not exactly match the consensus substrate sequences of PKCδ, it is possible that one or more of these Ser1179 kinases, upon activation/modulation by PKCδ, phosphorylate eNOS in response to thrombin. Although 5′-AMP-activated protein kinase was proposed to phosphorylate eNOS at Ser1179 by thrombin,24 a recent study has clearly eliminated this possibility.26

Thrombin exhibits its effect through the activation of G protein-coupled protease-activated receptors.8,9 Protease-activated receptor activation in endothelial cells results in intracellular signal transduction, involving Gq-stimulated phosphatidylinositol metabolism via phospholipase C-β, resulting in an increase in intracellular Ca2+ mobilization and PKC activation.10,11 This is in line with the findings presented here demonstrating that Gq, Ca2+, and PKCδ are all necessary components in the thrombin-induced phosphorylation of Ser1179 and activation of eNOS. Although we have not studied the molecular link between Ca2+ and PKCδ Tyr311 phosphorylation in the present study, we have shown recently that the elevation of Ca2+ could lead to PKCδ Tyr311 phosphorylation, a site critical for its enzymatic activity in VSMCs stimulated by the GPCR agonist angiotensin II.27 Therefore, it is likely that, in parallel with a phospholipase C/diacylglycerol-dependent PKCδ activation, intracellular Ca2+ elevation stimulates PKCδ activity through its Tyr311 phosphorylation in BAECs stimulated by thrombin.

Thors et al24 used human umbilical vein endothelial cells and ruled out the PKC pathway by using the data that PMA does not cause Ser1179 phosphorylation of eNOS. Although we have obtained similar results here, the findings could be interpreted as the complex regulation of eNOS by distinct PKC isoforms rather than the lack of positive regulation by the PKC pathway. Partovian et al28 demonstrated recently that PKCα is required for Ser1179 phosphorylation of eNOS and subsequent NO release in BAECs and human umbilical vein endothelial cells stimulated by a growth factor, FGF2. However, in the present study, dnPKCα has no inhibitory effect on Ser1179 eNOS phosphorylation by thrombin. FGF receptors activate phospholipase Cγ causing distinct time courses/patterns/amounts of intracellular Ca2+ formation and diacylglycerol production, which will likely lead to activation of distinct sets of PKC isoforms and eNOS regulation.

It should be noted that our findings are in contrast to previous publications dealing with Ser1179 phosphorylation of eNOS by stimulation of other GPCRs, including sphingosine 1-phosphate/the endothelial differentiation gene receptor, bradykinin/B2 receptor, and endothelin-1/endothelin B receptor. Sphingosine 1-phosphate/endothelial differentiation gene-stimulated Ser1179 eNOS phosphorylation is reported to require Gi, Ca2+, vascular endothelial growth factor receptor (Flk-1/kinase insert domain receptor) transactivation, PI3-K, and Akt.29–31 BK/B2-dependent phosphorylation partially requires Flk-1/kinase insert domain receptor transactivation and PI3-K as well.32,33 Endothelin-1/endothelin B receptor-dependent phosphorylation again requires Gi, Gβγ, PI3-K, and Akt.34 We have confirmed recently that thrombin-induced Ser1179 eNOS phosphorylation is not blocked by pertussis toxin (a Gi inhibitor) or overexpression of C terminus of G protein receptor kinase-2 (a Gβγ inhibitor; H Suzuki, S Eguchi, unpublished observation, 2006). Taken together, there should be at least 2 independent mechanisms of eNOS phosphorylation by GPCRs; 1 is used by a Gi-coupled receptor involving Flk-1/kinase insert domain receptor, PI3-K, and Akt, and the other is used by a Gq-coupled receptor involving Ca2+ and PKCδ.

Perspectives

Thrombin induces Ser1179 eNOS phosphorylation and activation through a Ca2+-dependent, PKCδ-sensitive, but PI3-K/Akt-independent pathway. Because dysfunction of endothelial NO production is one of the major predictors of cardiovascular events, these findings will contribute to a better understanding of the signaling mechanisms of thrombin in regulating the endothelial function. Therefore, further in vivo studies focusing on human pathophysiology in this area will contribute to the development of specific-acting drugs that can be used to treat and/or prevent endothelial dysfunctions.

Acknowledgments

Sources of Funding

This research was supported in part by National Institutes of Health National Center for Research Resources grant 2G12RR03032 and the American Heart Association (E.D.M.) and National Institutes of Health Heart, Lung, and Blood Institute grant HL076770 (S.E.).

Disclosures

None.

  • Received October 3, 2006.
  • Revision received October 18, 2006.
  • Accepted December 11, 2006.

References

  1. ↵
    Bosnjak JJ, Terata K, Miura H, Sato A, Nicolosi AC, McDonald M, Manthei SA, Saito T, Hatoum OA, Gutterman DD. Mechanism of thrombin-induced vasodilation in human coronary arterioles. Am J Physiol. 2003; 284: H1080–H1086.
    OpenUrl
  2. ↵
    Tesfamariam B, Allen G, Normandin D, Antonaccoio M. Involvement of the ‘tethered ligand’ receptor in thrombin-induced endothelium-mediated relaxations. Am J Physiol. 1993; 265: H1744–H1749.
    OpenUrlPubMed
  3. ↵
    Hamilton JR, Nguyen PB, Cocks TM. Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ Res. 1998; 82: 1306–1311.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Mizuno O, Hirano K, Nishimura J, Kubo C, Kanaide H. Mechanism of endothelium-dependent relaxation induced by thrombin in the pig coronary artery. Eur J Pharmacol. 1998; 351: 67–77.
    OpenUrlCrossRefPubMed
  5. ↵
    Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109 (supp III): III27–III32.
    OpenUrlCrossRefPubMed
  6. ↵
    Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn’t calcium/calmodulin enough? J Pharmacol Exp Ther. 2001; 299: 818–824.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol. 2003; 284: R1–R12.
    OpenUrl
  8. ↵
    Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A. 1999; 96: 11023–11027.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Grand RJ, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J. 1996; 313: 353–368.
    OpenUrlFREE Full Text
  10. ↵
    Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res. 2001; 88: 987–997.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol. 2004; 24: 41–53.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Eguchi S, Matsumoto T, Motley E, Utsunomiya H, Inagami T. Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. Possible requirement of Gq-mediated p21ras activation coupled to a Ca2+/calmodulin-sensitive tyrosine kinase. J Biol Chem. 1996; 271: 14169–14175.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Frank GD, Eguchi S, Yamakawa T, Tanaka S, Inagami T, Motley ED. Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II. Endocrinology. 2000; 141: 3120–3126.
    OpenUrlCrossRefPubMed
  14. ↵
    Ohba M, Ishino K, Kashiwagi M, Kawabe S, Chida K, Huh NH, Kuroki T. Induction of differentiation in normal human keratinocytes by adenovirus-mediated introduction of the eta and delta isoforms of protein kinase C. Mol Cell Biol. 1998; 18: 5199–5207.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Scotland RS, Morales-Ruiz M, Chen Y, Yu J, Rudic RD, Fulton D, Gratton JP, Sessa WC. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res. 2002; 90: 904–910.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, Marumo F, Hirata Y, Inagami T. Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem. 1999; 274: 36843–36851.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Eguchi S, Hirata Y, Imai T, Marumo F. C-type natriuretic peptide upregulates vascular endothelin type B receptors. Hypertension. 1994; 23: 936–940.
    OpenUrlPubMed
  18. ↵
    Sandoval R, Malik AB, Minshall RD, Kouklis P, Ellis CA, Tiruppathi C. Ca(2+) signalling and PKCalpha activate increased endothelial permeability by disassembly of VE-cadherin junctions. J Physiol. 2001; 533: 433–445.
    OpenUrlCrossRefPubMed
  19. ↵
    Yoshimura M, Oshima T, Matsuura H, Inoue T, Kambe M, Kajiyama G. Differential effects of extracellular Mg2+ on thrombin-induced and capacitative Ca2+ entry in human coronary arterial endothelial cells. Arterioscler Thromb Vasc Biol. 1997; 17: 3356–3361.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Konishi H, Yamauchi E, Taniguchi H, Yamamoto T, Matsuzaki H, Takemura Y, Ohmae K, Kikkawa U, Nishizuka Y. Phosphorylation sites of protein kinase C delta in H2O2-treated cells and its activation by tyrosine kinase in vitro. Proc Natl Acad Sci U S A. 2001; 98: 6587–6592.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 2001; 88: e68–e75.
    OpenUrlCrossRefPubMed
  22. ↵
    David-Dufilho M, Millanvoye-Van Brussel E, Topal G, Walch L, Brunet A, Rendu F. Endothelial thrombomodulin induces Ca2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II. J Biol Chem. 2005; 280: 35999–36006.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Takasaki J, Saito T, Taniguchi M, Kawasaki T, Moritani Y, Hayashi K, Kobori M. A novel Gαq/11-selective inhibitor. J Biol Chem. 2004; 279: 47438–47445.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Thors B, Halldorsson H, Thorgeirsson G. Thrombin and histamine stimulate endothelial nitric-oxide synthase phosphorylation at Ser1177 via an AMPK mediated pathway independent of PI3K-Akt. FEBS Lett. 2004; 573: 175–180.
    OpenUrlCrossRefPubMed
  25. ↵
    Suzuki H, Eguchi K, Ohtsu H, Higuchi S, Dhobale S, Frank GD, Motley ED, Eguchi S. Activation of endothelial nitric oxide synthase by the angiotensin II type-1 receptor. Endocrinology. 2006.; 147: 5914–5920.
    OpenUrlCrossRefPubMed
  26. ↵
    Stahmann N, Woods A, Carling D, Heller R. Thrombin activates AMP-activated protein kinase in endothelial cells via a pathway involving Ca2+/calmodulin-dependent protein kinase kinase beta. Mol Cell Biol. 2006; 26: 5933–5945.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Woolfolk EA, Eguchi S, Ohtsu H, Nakashima H, Ueno H, Gerthoffer WT, Motley ED. Angiotensin II-induced activation of p21-activated kinase 1 requires Ca2+ and protein kinase C delta in vascular smooth muscle cells. Am J Physiol. 2005; 289: C1286–C1294.
    OpenUrl
  28. ↵
    Partovian C, Zhuang Z, Moodie K, Lin M, Ouchi N, Sessa WC, Walsh K, Simons M. PKCalpha activates eNOS and increases arterial blood flow in vivo. Circ Res. 2005; 97: 482–487.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Igarashi J, Bernier SG, Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. Differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem. 2001; 276: 12420–12426.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, Walsh K, Hla T, Sessa WC. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001; 276: 19672–19677.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Tanimoto T, Jin ZG, Berk BC. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem. 2002; 277: 42997–43001.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem. 2001; 276: 16587–16591.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem. 2002; 277: 2028–2032.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Liu S, Premont RT, Kontos CD, Huang J, Rockey DC. Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt. J Biol Chem. 2003; 278: 49929–49935.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
March 2007, Volume 49, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Mechanism of Endothelial Nitric Oxide Synthase Phosphorylation and Activation by Thrombin
    Evangeline D. Motley, Kunie Eguchi, Myla M. Patterson, Phillip D. Palmer, Hiroyuki Suzuki and Satoru Eguchi
    Hypertension. 2007;49:577-583, originally published February 15, 2007
    https://doi.org/10.1161/01.HYP.0000255954.80025.34

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Mechanism of Endothelial Nitric Oxide Synthase Phosphorylation and Activation by Thrombin
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Mechanism of Endothelial Nitric Oxide Synthase Phosphorylation and Activation by Thrombin
    Evangeline D. Motley, Kunie Eguchi, Myla M. Patterson, Phillip D. Palmer, Hiroyuki Suzuki and Satoru Eguchi
    Hypertension. 2007;49:577-583, originally published February 15, 2007
    https://doi.org/10.1161/01.HYP.0000255954.80025.34
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Vascular Disease
    • Peripheral Vascular Disease
    • Thrombosis
  • Basic, Translational, and Clinical Research
    • Endothelium/Vascular Type/Nitric Oxide
    • Cell Signaling/Signal Transduction

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured